Skip to main content
. 2022 Aug 12;13:886701. doi: 10.3389/fimmu.2022.886701

Figure 3.

Figure 3

Effect of EV treatment on RSV replication. (A) A549 cells were infected with RSV alone (RSV) or treated with Mock-EVs (RSV+Mock-EVs) or RSV-EVs (RSV+RSV-EVs) (15 μg) for 24 hours and then infected with RSV (MOI of 1). (B) A549 cells were infected with RSV alone (RSV), pretreated with RSV-EVs (15 μg) 24 hours prior to RSV infection (RSV+RSV-EVs), infected with RSV and treated with Cerdulatinib (5 μM) 1h prior to infection (RSV-Cerd), or were pretreated with RSV-EVs for 24 hrs, treated with Cerd 1h prior to infection and then infected with RSV at a MOI of 1 (RSV+RSV-EVs+Cerd). Supernatants of infected cells were collected at 24 hours post-infection and viral titers were determined by plaque assay. Data are expressed as mean ± SEM. * indicates a statistical difference compared to RSV alone, while # indicates a difference between RSV-EV treated and RSV-EV treated plus Cerdulatinib groups (* or # for p ≤ 0.05). Data represents the mean average of three independent experiments.